Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients
Vanessa Roldán(Hospital Universitario Virgen de la Arrixaca), Gregory Y.H. Lip(Medical University of Białystok), Francisco Marı́n(Instituto Murciano de Investigación Biosanitaria), José Miguel Torregrosa Diaz(Hospital General Universitario Morales Meseguer), Begoña Muiña(Hospital General Universitario Morales Meseguer), Diana Hernández‐Romero(Hospital Universitario Virgen de la Arrixaca), Mariano Valdés(Universidad de Murcia), Vicente Vicente(Centro Regional de Hemodonación)
Cited by 132
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Antithrombotic Therapy for Atrial Fibrillation
|CHEST Journal|2012|919